Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash from Financing Activities (2019 - 2025)

C4 Therapeutics' Cash from Financing Activities history spans 7 years, with the latest figure at $118.7 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 105857.14% year-over-year to $118.7 million; the TTM value through Dec 2025 reached $126.4 million, up 178.8%, while the annual FY2025 figure was $126.4 million, 178.8% up from the prior year.
  • Cash from Financing Activities reached $118.7 million in Q4 2025 per CCCC's latest filing, up from $7.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $170.5 million in Q2 2021 to a low of -$10.8 million in Q3 2023.
  • Average Cash from Financing Activities over 5 years is $20.5 million, with a median of $361000.0 recorded in 2022.
  • The largest YoY upside for Cash from Financing Activities was 122606.38% in 2023 against a maximum downside of 3078.67% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $466000.0 in 2021, then crashed by 89.91% to $47000.0 in 2022, then skyrocketed by 122606.38% to $57.7 million in 2023, then crashed by 99.81% to $112000.0 in 2024, then soared by 105857.14% to $118.7 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Cash from Financing Activities are $118.7 million (Q4 2025), $7.8 million (Q3 2025), and -$46000.0 (Q1 2025).